The stock of Protagonist Therapeutics Inc (PTGX) has seen a -10.56% decrease in the past week, with a -15.99% drop in the past month, and a -7.08% decrease in the past quarter. The volatility ratio for the week is 5.41%, and the volatility levels for the past 30 days are at 4.20% for PTGX. The simple moving average for the last 20 days is -14.70% for PTGX’s stock, with a simple moving average of 8.36% for the last 200 days.
Is It Worth Investing in Protagonist Therapeutics Inc (NASDAQ: PTGX) Right Now?
Protagonist Therapeutics Inc (NASDAQ: PTGX) has a higher price-to-earnings ratio of 14.48x compared to its average ratio, The 36-month beta value for PTGX is at 2.20. Analysts have varying views on the stock, with 5 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for PTGX is 56.31M, and currently, shorts hold a 5.83% of that float. The average trading volume for PTGX on November 19, 2024 was 601.49K shares.
PTGX) stock’s latest price update
Protagonist Therapeutics Inc (NASDAQ: PTGX)’s stock price has dropped by -4.41 in relation to previous closing price of 40.39. Nevertheless, the company has seen a loss of -10.56% in its stock price over the last five trading days. accesswire.com reported 2024-11-19 that Webcast and conference call to be held be on Thursday, November 21st at 4:30 pm ET, dial in information below NEWARK, CA / ACCESSWIRE / November 19, 2024 / Protagonist Therapeutics, Inc. (“Protagonist” or the “Company”) today announced that the company will host a conference call and webcast to announce its oral peptide IL-17 antagonist development candidate and to share in vitro and pre-clinical proof-of-concept study results. Conference Call and Webcast Details The dial-in numbers for Protagonist’s investor update on Thursday, November 21st at 4:30 pm ET are: US-based Investors: 1-877-407-0752International Investors: 1-201-389-0912Conference Call ID: 13750274 The webcast link for the event can be found here: https://viavid.webcasts.com/starthere.jsp?ei=1698744&tp_key=f6482f31c0 A replay of the presentation will be available on the Company’s Investor Relations Events and Presentations webpage following the event.
Analysts’ Opinion of PTGX
Many brokerage firms have already submitted their reports for PTGX stocks, with Wedbush repeating the rating for PTGX by listing it as a “Outperform.” The predicted price for PTGX in the upcoming period, according to Wedbush is $58 based on the research report published on November 05, 2024 of the current year 2024.
TD Cowen, on the other hand, stated in their research note that they expect to see PTGX reach a price target of $65. The rating they have provided for PTGX stocks is “Buy” according to the report published on September 24th, 2024.
Truist gave a rating of “Buy” to PTGX, setting the target price at $60 in the report published on September 09th of the current year.
PTGX Trading at -15.00% from the 50-Day Moving Average
After a stumble in the market that brought PTGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -21.03% of loss for the given period.
Volatility was left at 4.20%, however, over the last 30 days, the volatility rate increased by 5.41%, as shares sank -15.62% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -12.77% lower at present.
During the last 5 trading sessions, PTGX fell by -9.23%, which changed the moving average for the period of 200-days by +50.65% in comparison to the 20-day moving average, which settled at $45.29. In addition, Protagonist Therapeutics Inc saw 68.38% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PTGX starting from Ali Asif, who sale 14,203 shares at the price of $44.49 back on Sep 11 ’24. After this action, Ali Asif now owns 34,960 shares of Protagonist Therapeutics Inc, valued at $631,872 using the latest closing price.
Waddill William D., the Director of Protagonist Therapeutics Inc, sale 8,000 shares at $45.00 during a trade that took place back on Sep 10 ’24, which means that Waddill William D. is holding 12,000 shares at $360,000 based on the most recent closing price.
Stock Fundamentals for PTGX
Current profitability levels for the company are sitting at:
- 0.46 for the present operating margin
- 0.99 for the gross margin
The net margin for Protagonist Therapeutics Inc stands at 0.53. The total capital return value is set at 0.27. Equity return is now at value 40.97, with 36.59 for asset returns.
Currently, EBITDA for the company is -90.34 million with net debt to EBITDA at -0.79. When we switch over and look at the enterprise to sales, we see a ratio of 6.79. The receivables turnover for the company is 121.32for trailing twelve months and the total asset turnover is 0.54. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.70.
Conclusion
In conclusion, Protagonist Therapeutics Inc (PTGX) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
